Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73299 | 0.97 | — | — | |
| SCHEMBL23573882 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL28937212 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| Ammonia Solution, Strong SCHEMBL4425485 | 0.95 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL28642695 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| Benzenethiol SCHEMBL9763283 | 0.83 | CNR1 (0.33) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL94414 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL13706022 | 0.81 | CNR1 (0.47) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL9879847 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR1CNR2ALOX5PTGS1 | |
| SCHEMBL355657 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845520-B1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | GOODYEAR TIRE & RUBBER (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11685712-B2 | Synthesis of monofunctional thiuram accelerator | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230029068-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | THE GOODYEAR TIRE & RUBBER COMPANY | 2023-01-26 | — | — | US | disclosed |
| EP-3845520-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | The Goodyear Tire & Rubber Company (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210198194-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | THE GOODYEAR TIRE & RUBBER COMPANY | 2021-07-01 | — | — | US | disclosed |
| EP-2552214-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1730110-B9 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011120026-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| EP-1730110-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | SMN1; SMN2 3957/4885CNR1 2744/4885CNR2 3381/4885 |
| US-20230029068-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | TST, TERT, MGMT | SMN1; SMN2 337/4885CNR1 4591/4885CNR2 4443/4885 |
| US-11685712-B2 | Synthesis of monofunctional thiuram accelerator | TST, TERT, MGMT | SMN1; SMN2 337/4885CNR1 4591/4885CNR2 4443/4885 |
| US-20210198194-A1 | SYNTHESIS OF MONOFUNCTIONAL THIURAM ACCELERATOR | TST, TERT, MGMT | SMN1; SMN2 337/4885CNR1 4591/4885CNR2 4443/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | SMN1; SMN2 4325/4885CNR1 1850/4885CNR2 2813/4885 |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | PRSS1, PRSS3, HPN | SMN1; SMN2 2871/4885CNR1 2469/4885CNR2 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.